Alnylam Pharmaceuticals
ALNY
ALNY
309 hedge funds and large institutions have $9B invested in Alnylam Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 122 increasing their positions, 80 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.44% less ownership
Funds ownership: 91.51% → 91.08% (-0.44%)
18% less capital invested
Capital invested by funds: $10.9B → $9B (-$1.92B)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Holders
309
Holding in Top 10
9
Calls
$106M
Puts
$56.4M
Top Buyers
| 1 | +$215M | |
| 2 | +$69M | |
| 3 | +$67.1M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$56.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$55.8M |
Top Sellers
| 1 | -$724M | |
| 2 | -$102M | |
| 3 | -$39.6M | |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$35.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$28.6M |